678 related articles for article (PubMed ID: 32118506)
21. Salvage Therapy Using Bacillus Calmette-Guérin Derivatives or Single Agent Chemotherapy.
Haas CR; McKiernan JM
Urol Clin North Am; 2020 Feb; 47(1):47-54. PubMed ID: 31757299
[TBL] [Abstract][Full Text] [Related]
22. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.
Nepple KG; Lightfoot AJ; Rosevear HM; O'Donnell MA; Lamm DL;
J Urol; 2010 Nov; 184(5):1915-9. PubMed ID: 20846688
[TBL] [Abstract][Full Text] [Related]
23. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
24. The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer.
Guevara A; Salomon L; Allory Y; Ploussard G; de la Taille A; Paul A; Yiou R; Hoznek A; Dahan M; Abbou CC; Vordos D
J Urol; 2010 Jun; 183(6):2161-4. PubMed ID: 20399454
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.
Dalbagni G; Russo P; Bochner B; Ben-Porat L; Sheinfeld J; Sogani P; Donat MS; Herr HW; Bajorin D
J Clin Oncol; 2006 Jun; 24(18):2729-34. PubMed ID: 16782913
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy.
Lee JY; Diaz RR; Cho KS; Lim MS; Chung JS; Kim WT; Ham WS; Choi YD
J Urol; 2013 Oct; 190(4):1192-9. PubMed ID: 23648222
[TBL] [Abstract][Full Text] [Related]
27. A prospective comparative study of intravesical bacillus Calmette-Guérin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer.
Sengiku A; Ito M; Miyazaki Y; Sawazaki H; Takahashi T; Ogura K
J Urol; 2013 Jul; 190(1):50-4. PubMed ID: 23376145
[TBL] [Abstract][Full Text] [Related]
28. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guérin plus interferon-α.
Rosevear HM; Lightfoot AJ; Nepple KG; O'Donnell MA
J Urol; 2011 Jan; 185(1):67-71. PubMed ID: 21074202
[TBL] [Abstract][Full Text] [Related]
30. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
Nakai Y; Anai S; Tanaka N; Chihara Y; Haramoto M; Otani T; Nakagawa Y; Hirao Y; Konishi N; Fujimoto K
Int J Urol; 2016 Oct; 23(10):854-860. PubMed ID: 27416975
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions.
Serretta V; Galuffo A; Pavone C; Allegro R; Pavone-MacAluso M
Urology; 2005 Jan; 65(1):65-9. PubMed ID: 15667865
[TBL] [Abstract][Full Text] [Related]
32. Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial.
Perdonà S; Di Lorenzo G; Cantiello F; Damiano R; De Sio M; Masala D; Bruni G; Gallo L; Federico P; Quattrone C; Pizzuti M; Autorino R
Anticancer Drugs; 2010 Jan; 21(1):101-6. PubMed ID: 19858710
[TBL] [Abstract][Full Text] [Related]
33. The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer.
Packiam VT; Richards J; Schmautz M; Heidenreich A; Boorjian SA
Curr Opin Urol; 2021 May; 31(3):178-187. PubMed ID: 33742981
[TBL] [Abstract][Full Text] [Related]
34. Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer.
Meng MV; Gschwend JE; Shore N; Grossfeld GD; Mostafid H; Black PC
J Urol; 2019 Dec; 202(6):1111-1119. PubMed ID: 31042108
[TBL] [Abstract][Full Text] [Related]
35. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
36. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
37. US Clinical Practice Patterns of Intravesical Chemotherapy for Bacillus Calmette-Guérin-Unresponsive and Bacillus Calmette-Guérin-Exposed Nonmuscle-Invasive Bladder Cancer.
Abou Chakra M; Shore ND; Dillon R; O'Donnell MA
Urol Pract; 2024 Jan; 11(1):97-107. PubMed ID: 37903746
[TBL] [Abstract][Full Text] [Related]
38. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy.
Barlow L; McKiernan J; Sawczuk I; Benson M
BJU Int; 2009 Oct; 104(8):1098-102. PubMed ID: 19389012
[TBL] [Abstract][Full Text] [Related]
39. Prospective phase II trial of alternating intravesical Bacillus Calmette-Guérin (BCG) and interferon alpha IIB in the treatment and prevention of superficial transitional cell carcinoma of the urinary bladder: preliminary results.
Bazarbashi S; Raja MA; El Sayed A; Ezzat A; Ibrahim E; Kattan S; Kardar A; Peracha A; Lindstedt E; Hanash K
J Surg Oncol; 2000 Jul; 74(3):181-4. PubMed ID: 10951412
[TBL] [Abstract][Full Text] [Related]
40. Conservative treatment of high grade superficial bladder tumours.
Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]